Nohui Health received $30 million in E-round financing to complete China's first early cancer screening product ahead of schedule.

On July 10, Nohuco Health, China's first bio-high-tech company focused on early cancer screening, today announced the completion of a $30 million E-round financing led by Rock Springs Capital, led by Orbi Med, Lilly Asia Fund (LAV), Cormorant Asset Management, China Resources Zhengda Life Sciences Fund, Octagon Capital and veteran shareholder Qiming Venturesso far, Nochhealth has received the continued attention of the world's leading venture capital, top biohealth funds and long-term investment institutions, with a total investment of more than $160 million, making it the most popular company for investors in cancer screeningNohui Health was founded in 2013 to create the early screening market for colorectal cancer in Chinaits independent research and development of "non-invasive multi-target fecal FIT-DNA joint detection" products - Chang Weiqing ® is China's first early screening products for bowel cancer, after Exact Sciences, the U.Scancer early screening benchmark company, Nohui Health became the second company in the world to complete large-scale prospective multicenter clinical trials of early cancer screening products in Chinathe trial was officially launched in September 2018 under the guidance and supervision of the State Drug Administration, and jointly covered eight large tertiary hospitals across the country, with a cumulative total of nearly 6,000 cases, and all clinical data were submitted by early 2020this round of financing will be used to consolidate the expansion of the scale of its main cancer early sieve products, accelerate the development of new products, clinical research and market transformation, practice innovative diversification market strategy, to build Nohui Health as "China's cancer early screening first brand" core competitiveness.